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ABSTRACT
The expected lifespan of persons living with human immunodeficiency virus (PLWH) has increased
significantly due to improved treatment options. However, an unintended consequence has been an
increased prevalence of chronic diseases such as type 2 diabetes mellitus (T2D). It is therefore important to
explore the underlying biological mechanisms for this increased risk of T2D among PLWH since it is not
yet well understood. Investigation of specific biomarkers could help define the pathogenesis of T2D in
PLWH and yield many positive outcomes including the detection of ‘at risk’ individuals as targets of early
interventional strategies along with identification of new diagnostic criteria. PURPOSE: The primary aim
of this research was to identify specific biomarkers which differentiate PLWH and those comorbid with
HIV and T2D (PLWH+T2D). METHODS: 16 PLWH (47.92.7 y/o; 10 male) and 16 clinically diagnosed
PLWH+T2D (53.61.4 y/o; 10 male) were recruited for the study. Blood was drawn via venipuncture for
assessment of HbA1c and biomarkers associated with inflammation (IL-1β, IL-6, hs-CRP, insulin,
adiponectin, leptin, and TNF-α, along with soluble receptor counterparts sIL-1RI, sIL-1RII, sIL-6RI, sTNFRI, and sTNF-RII), vascular function (ADAMTS13, slCAM-1, sVCAM-1, SAA, and, SAP), and coagulation
activation (fibrinogen, D-dimer, and, vWF). RESULTS: As expected, HbA1c was lower in PLWH
compared with PLWH+T2D (5.80.1 vs 7.00.4%, p<0.05). As further confirmation of a diabetes diagnosis,
all individuals in the PLWH+T2D group were taking prescribed oral diabetes medication. Predictably, hsCRP levels were elevated; however, not significantly different between groups (7.81.4 vs 11.02.8 mg/L,
p>0.05). Differences were found between PLWH and PLWH+T2D in indicators of coagulation activation,
specifically vWF (2.390.42 vs 3.880.55 mg/dL, p<0.05) and fibrinogen (1425103.1 vs 1914184.2 ng/mL,
p<0.05). No significant differences between PLWH and PLWH+T2D were seen in any of the biomarkers
associated with vascular function or inflammation. CONCLUSION: We believe this is the first time
biomarkers of vascular function and coagulation activation have been assessed in this comorbid
population. The significant increase in vWF and fibrinogen in PLWH+T2D compared with PLWH suggest
that pathways involving coagulation may be the first ones altered in the transition to this co-morbid state.
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